ClinicalTrials.gg
Active, not recruitingNCT03853616Updated Oct 9, 2026

MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)

A Phase 1 interventional study of MB-CART19.1 in Acute Lymphoblastic Leukemia Recurrent, B-cell Lymphoma Recurrent and B-cell Lymphoma Refractory, sponsored by Miltenyi Biomedicine GmbH. Active, not recruiting at 9 sites in Germany. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Miltenyi Biomedicine GmbH · Phase 1, Interventional, and Treatment

How we know

Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
1 Year and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 144 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in Germany — 22 open to participants now, 38 under way, 17 of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Germany.

Planned enrollment
109th of 132
48 · median 173
Started
2018
with 3 others
Phase 1
20 of 144
1 open now
Primary completion
2026-11
later than 5 of 37 live
Registered
105th of 144
by date

Among the 144 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in Germany, this one is the 109th largest by planned enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2018, is one of 20 in phase 1, reaches primary completion later than 5 of the 37 other live ones, and was the 105th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,039 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

22 of the 144 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in Germany are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 151 (81%) set no upper age limit and 15 (8%) stop at 75 or younger; 18 take children under 18; 12 take healthy volunteers.

This study: 1 Year and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Leukemia, Lymphocytic, Chronic, B-Cell with a site in Germany, or all of them as a file.
02

Study summary

This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. In total approximately 48 patients will be included in the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).

Read the detailed description

This trial will evaluate the safety of the MB-CART19.1 and determine the recommended dose levels for each of the three disease cohorts.

Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1 and in Cohort 3 with Dose Level 2, sparing Dose Level 1 (see figure 1). Each of the cohorts will evaluate the safety of MB-CART19.1.

In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable.

Cohort 3 will Start with Dose Level 2. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. DLT will be evaluated within 4 weeks after the infusion of MB-CART19.1. An interval of at least 28 days between the treatment of the first and the second patient in each dose level (and in each cohort) is mandatory.

03

Conditions studied

  • Acute Lymphoblastic Leukemia Recurrent
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • Chronic Lymphocytic Leukemia Recurrent
  • Chronic Lymphocytic Leukemia Refractory
04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients must have r/r CD19-expressing ALL or NHL/CLL
  • CD19 expression must be detected on the malignant cells by flow cytometry (leukemia, malignant effusion in NHL) or immunohistochemistry (NHL);
  • Age ≥ 1 year (if deemed fit by treating investigator);
  • Absolute CD3+ T cell count ≥100/μl;
  • performance score of 0-2 if >16 years old, or Lansky performance score of >50 if ≤16 years old at screening;
  • No active , , HIV1/2;
  • No or negative pregnancy test at screening and before chemotherapy in women with childbearing potential;
  • Signed and dated /assent by patients
  • and meet the following disease-specific criteria:

ALL:

  • patients with >5% blasts in BM (M2 or M3) after at least one standard chemotherapy and one salvage regimen who are ineligible for stem cell transplant (alloSCT) or have disease activity precluding alloSCT at this time, or
  • patients who have relapsed post alloSCT at least 100 days posttransplant, with no evidence of active , and no longer taking agents for at least 30 days prior to enrollment.
  • patients with Ph+ ALL if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have r/r disease after treatment with at least 2 different TKIs.
  • ALL patients with combined bone marrow and CNS and/or testicular relapse are eligible only if the extramedullary disease has been successfully cleared by conventional therapy at the time of inclusion (e.g. intrathecal chemotherapy, orchiectomy).

Pediatric aggressive NHL (1-17 years):

  • patients after at least one salvage chemotherapy as bridge to alloSCT or
  • patients ineligible for alloSCT or
  • patients who have relapsed post alloSCT at least 100 days posttransplant, with not evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.
  • patients with CNS disease (excluding isolated CNS lymphoma) are eligible only if disease has been successfully cleared by intrathecal chemotherapy at the time of inclusion.

Adult NHL:

  • patients after at least one standard chemotherapy and one salvage regimen as bridge to alloSCT or
  • patients who are ineligible for alloSCT or
  • patients who have relapsed post alloSCT at least 100 days posttransplant, with no evidence of active GVHD, and no longer taking immunosuppressive agents for at least 30 days prior to enrollment.
  • patients with CNS disease (excluding isolated CNS lymphoma) are eligible only if disease has been successfully cleared by intrathecal chemotherapy at the time of inclusion.

CLL:

  • patients with r/r disease after established and approved treatment options have failed.
  • patients not eligible or appropriate for conventional alloSCT.

Exclusion criteria

Exclusion Criteria:

  • Isolated CNS or testicular relapse in ALL;
  • Isolated CNS lymphomas;
  • Active solid or history of solid brain metastases
  • Current disease, or history of autoimmune disease with potential CNS involvement;
  • Active CNS dysfunction (including but not limited to uncontrolled seizure disorders, cerebrovascular ischemia or hemorrhage, dementia, paralysis);
  • History of an additional other than non-melanoma skin cancer or carcinoma in situ unless disease free for ≥3 years;
  • Pulmonary function: Patients with pre-existing severe lung disease or an oxygen requirement of >28% O2 supplementation or active pulmonary infiltrates on chest X-ray;
  • Cardiac function: Fractional shortening \<28% or \<50% by echocardiography;
  • Renal function: ≤29 mL/min/1.73 m2 by CKD-EPI for patients 18 yrs (Levey et al. 2009) or ≤29 mL/min/1.73 m2 by Schwartz formula (Schwartz et al. 1976) for patients \<18 yrs of age;
  • Liver function: Patients with a serum >3 times or an or ALT > 5 times upper limit of normal, unless due to leukemic liver infiltration in the estimation of the investigator;
  • Rapidly progressive disease that in the estimation of the investigator would compromise ability to complete study therapy;
  • Pregnant or breast-feeding females;
  • Medications:

    • Systemic chemotherapies, with the exception of physiologic replacement dosing, tyrosine kinase inhibitors (TKI) within 7 days prior to leukapheresis,
    • Fludarabine/clofarabine or drugs and antibodies (e.g. rituximab, calcineurin inhibitors, blinatumomab) or drugs or donor lymphocyte transfusions or radiation therapy within 30 days prior to apheresis,
    • Alemtuzumab within 3 months prior to leukapheresis,
    • Exception: Intrathecal chemotherapy is allowed prior to treatment, but should be discontinued in ALL and BL 10 days prior to MB-CART19.1 infusion to limit risk of neurotoxicities;
  • against any drug or its ingredients/impurities that is scheduled or likely to be given during trial participation, e.g. as part of the mandatory lymphodepletion protocol, pre-medication for infusion, rescue medication/salvage therapies for treatment related toxicities;
  • Intake of concomitant medication for other reasons than hypersensitivity, e.g. and fludarabine;
  • Contraindication of trial related procedures as judged by the investigator, e.g. lumbar punctures for CSF sampling;
  • Female patients of not willing to practice a highly effective form of from the time of enrollment and for 12 months after dosing the IMP;
  • Male patients of fathering potential not willing to practice a highly effective form of birth control from the time of enrollment and for 12 months after dosing the IMP;
  • Concurrent participation in another interventional trial that could interact with this trial, e.g. CAR T trials;
  • Cerebral dysfunction, legal incapacity of adult patients;
  • Committal to an institution on judicial or official order.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    DL 0: 1x10e5 MB-CART19.1 cells

    In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.

    Biological: MB-CART19.1

  • Experimental
    DL 1: 5x10e5 MB-CART19.1 cells

    Dose evaluation will start in Cohorts 1 and 2 with Dose Level 1. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.

    Biological: MB-CART19.1

  • Experimental
    DL 2: 1x10e6 MB-CART19.1 cells

    Dose evaluation will start in Cohort 3 with Dose Level 2, sparing Dose Level 1. If Dose Level 2 is not tolerated, Dose Level 1 will be tested. In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD.

    Biological: MB-CART19.1

  • Experimental
    DL 3: 3x10e6 MB-CART19.1 cells

    In each dose level of each of the three cohorts three 3 + 3 patients will be treated. A particular dose level will be expanded to 6 patients if one patient out of 3 patients treated at that particular dose level develops DLT. Once this occurs, further dose-escalations are halted until the dose has proven to be safe in the expanded cohort. If 2 or more in a cohort of 6 patients develop DLT no further dose escalation is allowed, and the next lower dose level will be expanded to 6 patients in total. The highest dose among the dose levels tested at which no more than one out of six patients experiences DLT will be considered the MTD. In Dose Level 3, three additional patients will be treated, if no DLT occurred. Dose Level 0 will be tested only if Dose Level 1 is not tolerable.

    Biological: MB-CART19.1

Interventions

06

What researchers measure

Primary outcomes

  1. Determination of the recommended dose of MB-CART19.1

    Maximum tolerated dose (MTD), defined as the highest dose level of the two to three dose levels tested at which \<33% of patients experience DLT until day 28 after infusion of MB-CART19.1, on the basis of safety and toxicity assessment of MB-CART19.1 per adverse events (AE) reporting classified according to CTCAE version 5.0.

    Time frame: until day 28 after infusion of MB-CART19.1

Secondary outcomes

  1. Overall incidence and severity of adverse events

    per adverse events (AE) reporting classified according to CTCAE version 5.0

    Time frame: through study completion, an average of 5 years

  2. Response to treatment for each timepoint

    ORR in ALL (Rate of CR/CRh)

    Time frame: day 28

  3. Response to treatment for each timepoint

    Rate MRD-negative CR in ALL

    Time frame: day 28, week 12, month 6, 1 year

  4. Response to treatment for each timepoint

    ORR in NHL/CLL (Rate of CR/PR)

    Time frame: day 28, patients not in CR on day 28: month 3

  5. Occurence of B-cell depletion

    Circulating B cell numbers

    Time frame: through study completion, an average of 5 years

  6. Phenotype and persistence of MB-CART19.1

    Blood samples for determination of persistence/phenotyping of infused MB-CART19.1 will be analysed

    Time frame: days 2, 7, 10, 14, 28, weeks 8, 12, months 6, 12, 24, 36, 48, 60

  7. Number of patients with successful MB-CART19.1 production

    Number of patients meeting the inclusion criteria and none of the exclusion criteria for who an autologous MB-CART19.1 product can be generated

    Time frame: day 0

  8. Rate of ALL patients achieving MRD negative CR

    Rate MRD-negative CR in ALL

    Time frame: day 28, week 12, month 6, 1 year

  9. Duration of response

    Determination of response rate

    Time frame: through study completion, an average of 5 years

  10. Disease-free survival

    disease-free survival at 1 year after adoptive immunotherapy with MB-CART19.1 in patients not receiving alloSCT

    Time frame: at 1 year after MB-CART19.1 infusion in patients not receiving alloSCT

  11. Overall survival

    overall survival at 1 year after adoptive immunotherapy with MB-CART19.1 in patients not receiving alloSCT

    Time frame: at 1 year after MB-CART19.1 infusion in patients not receiving alloSCT

07

Study locations

9 sites
  • Charité - University clinic, pediatric clinic with focus on oncology and hematology
    Berlin, 13353, Germany
  • Universitätsklinikum Erlangen
    Erlangen, 91054, Germany
  • University medicine Goettingen, Clinic of hematology and medical oncology
    Göttingen, 37075, Germany
  • Children's Hospital of Dr. von Hauner by Ludwig-Maximilian University
    Munich, 80337, Germany
  • Universitätsklinikum Münster - Klink für Kinderheilkunde und Jugendmedizin / Pädiatrische Hämatologie und Onkologie
    Münster, 48149, Germany
  • Universitätsklinikum Münster - Medizinische Klinik A / KMT Zentrum
    Münster, 48149, Germany
  • Tuebingen University clinic, medical university clinic for internal medicine
    Tübingen, 72076, Germany
  • University clinic for children and youth medicine
    Tübingen, 72076, Germany
  • University clinic, pediatric hematology and oncology
    Würzburg, 97070, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2018 (actual). Primary completion is estimated for Nov 2026, 96 months after the start.

Of 84 industry-sponsored phase 1 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's planned 96 months is above that.

Counting every sponsor, half of 180 studies reached it within 56 months; a quarter within 39 and three quarters within 86.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Sep 2026 → Nov 2026 and completion Sep 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2019
First posted
Feb 25, 2019
StartActual
Nov 26, 2018
Primary completionEst.
Nov 2026was Sep 2026
CompletionEst.
Nov 2026was Sep 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Nov 2026
Oct 9, 2026
Study completion
Sep 2026→Nov 2026
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Sep 2026→Nov 2026
    Study completion Sep 2026→Nov 2026
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03853616
Lead sponsor
Miltenyi Biomedicine GmbH
Responsible party
Sponsor
First posted
Feb 25, 2019
Start date
Nov 26, 2018
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 9, 2026

Study contacts

Claudia Rössig, Prof. Dr.
principal investigator · Univeristy Hospital Muenster

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1

Start the discussion